Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.57 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.57 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262740 | 0.97 | MAP2K1 (0.56) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6264248 | 0.92 | MEN1 (0.62) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6262830 | 0.92 | MAP2K1 (0.58) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6260609 | 0.92 | MAP2K1 (0.54) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6264913 | 0.90 | MEN1 (0.60) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6264011 | 0.90 | MAP2K1 (0.59) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6261631 | 0.89 | MEN1 (0.47) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6264102 | 0.89 | MAP2K1 (0.54) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6261872 | 0.89 | MAP2K1 (0.55) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6263489 | 0.87 | MAP2K1 (0.58) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144371-B1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-11-09 | — | — | EP | claimed |
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2003-05-15 | — | — | US | claimed |
| JP-2003504401-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| EP-1144371-B1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6750217-B2 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS; KINASE INHIBITOR | WARNER-LAMBERT COMPANY | 2004-06-15 | — | — | US | disclosed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2003-05-15 | — | — | US | disclosed |
| US-6440966-B1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092748-A1 | Benzenesulfonamide derivatives and their use as MEK inhibitors | NR2E1, NR0B1, NR0B2 | MAP2K1 219/4885MAP2K2 108/4885RAF1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.